BeOne Medicines (ONC) vs Roivant Sciences (ROIV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Roivant Sciences (ROIV) has outperformed BeOne Medicines (ONC) over the past year, gaining 115.6% versus a gain of 6.6%. Over five years, ROIV leads with a +477.2% price change compared with +1.6% for ONC. BeOne Medicines is the larger company by market cap ($39.22 billion vs $24.67 billion), about 1.6 times the size.
BeOne Medicines converts more of its revenue into profit, with a net margin of 5.4% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | ROIV |
|---|---|---|
| Share price | $344.74 | $34.15 |
| Market cap | $39.22B | $24.67B |
| 1-day change | -5.30% | -1.73% |
| YTD return | +19.82% | +60.14% |
| 1-year return | +6.56% | +115.57% |
| 5-year return | +1.56% | +477.24% |
| P/E ratio (TTM) | 61.67 | — |
| Forward P/E | 33.63 | — |
| EPS (TTM) | $5.59 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.34B | $8.26M |
| Revenue growth (YoY) | +40.23% | -71.57% |
| Net income (latest FY) | $286.93M | $-299.77M |
| Gross margin | 87.49% | — |
| Operating margin | 8.37% | -6235.69% |
| Net margin | 5.37% | -3629.19% |
| 52-week high | $385.22 | $42.50 |
| 52-week low | $253.95 | $15.90 |
| Distance from 52-week high | -10.51% | -19.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.24% | +40.79% |
| Average volume | 388.88K | 7.02M |
| Shares outstanding | 104.92M | 722.32M |
| Employees | 12,000 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed ONC by 109.0 percentage points over the past year.
- BeOne Medicines is more profitable, keeping 5.4 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs -71.57%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
ONC vs ROIV FAQ
Which is bigger, BeOne Medicines or Roivant Sciences?
BeOne Medicines (ONC) is larger, with a market capitalization of $39.22B compared with $24.67B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ONC or ROIV?
ROIV returned +115.57% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Are BeOne Medicines and Roivant Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.